Jennifer Doudna: How CRISPR lets us edit our DNA
Jennifer Doudna: Como editar o ADN con CRISPR
Jennifer Doudna was part of inventing a potentially world-changing genetic technology: the gene editing technology CRISPR-Cas9. Full bio
Double-click the English transcript below to play the video.
para editar xenomas.
for editing genomes.
scientists to make changes
aos científicos facer cambios
to cure genetic disease.
que a tecnoloxía CRISPR
through a basic research project
how bacteria fight viral infections.
con virus na súa contorna,
in their environment,
like a ticking time bomb --
to defuse the bomb
para destruír a bomba
an adaptive immune system called CRISPR,
teñen nas súas células
chamado CRISPR
ADN vírico e destruílo.
viral DNA and destroy it.
é una proteína que se chama Cas9
is a protein called Cas9,
cortar e degradar o ADN viral
and eventually degrade viral DNA
of this protein, Cas9,
que podíamos modificar a súa función
harness its function
specific bits of DNA into cells
para facer cousas
been possible in the past.
para cambiar o ADN
has already been used
of mice and monkeys,
hai pouco que poden usar
the CRISPR technology
en embrións humanos.
probaron que podían usar CRISPR
they could use CRISPR
of an integrated HIV virus
este tipo de edición xenética
of genome editing
that we have to consider,
not only in adult cells,
non só se pode usar en células adultas
sobre a tecnoloxía que coinventei,
about the technology that I co-invented,
and societal implications
todas as implicacións éticas e sociais
what the CRISPR technology is,
a prudent path forward
á hora de empregala.
they inject their DNA.
to be plucked out of the virus,
into the chromosome --
get inserted at a site called CRISPR.
interspaced short palindromic repeats.
palindrómicas cortas
interespazadas".
we use the acronym CRISPR.
to record, over time,
are passed on to the cells' progeny,
not only in one generation,
un rexistro de infeccións.
to keep a record of infection,
Blake Wiedenheft, likes to say,
a genetic vaccination card in cells.
into the bacterial chromosome,
of a molecule called RNA,
of the viral DNA.
with DNA molecules
from the CRISPR locus
to protein called Cas9,
like a sentinel in the cell.
of the DNA in the cell,
the sequences in the bound RNAs.
the blue molecule is DNA --
to cut up the viral DNA.
sentinela-Cas9-ARN,
sentinel complex
that can cut DNA --
in the DNA helix.
this complex is programmable,
particular DNA sequences,
could be harnessed for genome engineering,
a very precise change to the DNA
this break was introduced.
a word-processing program
usar o sistema CRISPR
the CRISPR system for genome engineering
to detect broken DNA
de detectar ADN roto e reparalo.
a double-stranded break in its DNA,
the ends of the broken DNA
in the sequence of that position,
na secuencia desa posición,
a new piece of DNA at the site of the cut.
double-stranded breaks into DNA
to repair those breaks,
of new genetic information.
the CRISPR technology
causing cystic fibrosis, for example,
a reparar esa mutación.
to repair that mutation.
it's been in development since the 1970s.
were very promising,
that they were either inefficient,
for use in their own laboratories,
clinical applications.
like CRISPR and utilize it has appeal,
enxeñería xenómica máis vellas,
genome engineering technologies
to rewire your computer
a new piece of software,
novo software.
is like software for the genome,
using these little bits of RNA.
unha rotura de cadea dobre
break is made in DNA,
astounding things,
potencialmente asombrosos.
that cause sickle cell anemia
da técnica CRISPR
applications of the CRISPR technology
to deliver this tool into cells,
en que se traballa
that's going on
of human disease, such as mice.
de enfermidades humanas,
very precise changes
cambios precisos no ADN celular,
that these changes in the cell's DNA
in this case, an entire organism.
interromper un xene
was used to disrupt a gene
for the black coat color of these mice.
differ from their pigmented litter-mates
in the entire genome,
from these animals,
no sitio onde foi inducido
where we induced it,
con outros animais
are going on in other animals
for human disease,
that we can use these systems
que podemos usar estes sistemas
in particular tissues,
the CRISPR tool into cells.
logo de cortado
that DNA is repaired after it's cut,
and limit any kind of off-target,
of using the technology.
clinical application of this technology,
desta tecnoloxía,
that we will see clinical trials
que vexamos ensaios clínicos
therapies within that time,
to think about.
around this technology,
arredor desta tecnoloxía,
in start-up companies
en empresas emerxentes
a tecnoloxía CRISPR,
to commercialize the CRISPR technology,
in these companies.
en mellora xenética.
for things like enhancement.
to engineer humans
such as stronger bones,
to cardiovascular disease
a enfermidades cardiovasculares
to be desirable,
or to be taller, things like that.
would give rise to these traits
to make such changes,
that we have to carefully consider,
chamamos a una pausa mundial
have called for a global pause
of the CRISPR technology in human embryos,
implications of doing so.
deste tipo de experimentación.
precedent for such a pause
hai un precedente importante
on the use of molecular cloning,
da clonación molecular,
could be tested carefully and validated.
are not with us yet,
are happening right now.
a huge responsibility,
gran responsabilidade,
both the unintended consequences
of a scientific breakthrough.
nun descubrimento científico.
esta é unha tecnoloxía
a technology with huge consequences,
or a moratorium or a quarantine
moratoria ou corentena,
os resultados terapéuticos,
the therapeutic results of this,
gaining traction,
of The Economist -- "Editing humanity."
it's not about therapeutics.
did you get back in March
for a moment and think about it?
were actually, I think, delighted
de ter a ocasión
to discuss this openly.
falar coa xente,
as well as others,
of viewpoints about this.
careful consideration and discussion.
happening in December
unha gran reunión en decembro,
e outros.
of Sciences and others,
a nivel práctico?
out of the meeting, practically?
de diferentes individuos
and stakeholders
this technology responsibly.
tecnoloxía de xeito responsable.
a consensus point of view,
de Harvard,
for example, at Harvard,
are just a question of safety.
in animals and in labs,
we move on to humans."
pensamento,
school of thought,
this opportunity and really go for it.
e aproveitala.
se divida por isto?
in the science community about this?
some people holding back
or don't regulate at all?
pouco ou nada.
como en calquera nova tecnoloxía,
especially something like this,
a variety of viewpoints,
perfectly understandable.
for human genome engineering,
consideration and discussion
e campos da ciencia
and other fields of science
exponencialmente.
pretty much like yours.
intelligence, autonomous robots and so on.
dos robots autónomos de guerra,
a similar discussion in those fields,
serve as a blueprint for other fields?
para os científicos saír do laboratorio.
to get out of the laboratory.
uncomfortable to do that.
in the genesis of this
in a position of responsibility.
that other technologies
something that could have implications
ás charlas TED.
ABOUT THE SPEAKER
Jennifer Doudna - BiologistJennifer Doudna was part of inventing a potentially world-changing genetic technology: the gene editing technology CRISPR-Cas9.
Why you should listen
Together with her colleague Emmanuelle Charpentier of Umeå University in Sweden, Berkeley biologist Jennifer Doudna is at the center of one of today's most-discussed science discoveries: a technology called CRISPR-Cas9 that allows human genome editing by adding or removing genetic material at will. This enables fighting genetic diseases (cutting out HIV, altering cancer cells) as well as, potentially, opening the road to "engineered humans."
Because some applications of genetic manipulation can be inherited, Doudna and numerous colleagues have called for prudent use of the technology until the ethics and safety have been properly considered.
Doudna is the co-winner of the 2018 Kavli Prize in Nanoscience, along with Emmanuelle Charpentier and Virginijus Šikšnys.
Jennifer Doudna | Speaker | TED.com